Assessing overall duration of cardiovascular medicines in veterans with established cardiovascular disease

European Journal of Preventive Cardiology

Volumn 17, Issue 1, 2010, Pages 71-76

  Roughead, Elizabeth E ^a   Vitry, Agnes I ^a   Preiss, Adrian Kym ^a   Barratt, John D ^a   Gilbert, Andrew L ^a   Ryan, Philip ^b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

aged; cardiovascular drugs; medication adherence

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THROMBOCYTE ANTIBODY;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; HEART DISEASE; HEART MUSCLE ISCHEMIA; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VETERAN;

AGED; AGED, 80 AND OVER; AUSTRALIA; CARDIOVASCULAR AGENTS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MYOCARDIAL ISCHEMIA; RETROSPECTIVE STUDIES; TIME FACTORS; VETERANS;

EID: 77149172871     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32832f3b56     Document Type: Article

References (25)

1. Medicare Australia. Pharmaceutical Benefits Schedule item statistics. 2006 [cited 2006 24 April]; Available from: http://www.medicareaustralia.gov.au/statistics/dyn_pbs/forms/pbs_tab1.shtml.
2. Therapeutic Guidelines Ltd. e-TG complete. North Melbourne: Therapeutic Guidelines Ltd; 2006.
3. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ 2006; 333: 15.
4. Nelson MR, Reid CM, Ryan P, Willson K, Yelland L. Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2). Med J Aust 2006; 185: 487–489.
5. Australian Institute of Health and Welfare: Senes S, Penm E, Medicines for cardiovascular health: are they used appropriately?, in Cardiovascular disease series no 27. Cat. no. 36. Canberra: AIHW; 2007.
6. Simons LA, Ortiz M, Calcino G. Persistence with antihypertensive medication: Australia-wide experience, 2004–2006. Med J Aust 2008; 188: 224–227.
7. Elliott RA, Ross-Degnan D, Adams AS, Safran DG, Soumerai SB. Strategies for coping in a complex world: adherence behavior among older adults with chronic illness. J Gen Intern Med 2007; 22: 805–810.
8. Roughead EE, Ramsay E, Priess K, Barratt J, Ryan P, Gilbert AL. Medication adherence, first episode duration, overall duration and time without therapy: the example of bisphosphonates. Pharmacoepidemiol Drug Saf 2009; 18: 69–75.
9. Australian Government Department of Health and Ageing. Guidelines for preparing submissions for the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra: Australian Government Department of Health and Ageing; 2008.
10. Hughes DA, Bagust A, Haycox A, Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Econ 2001; 10: 601–615.
11. Hughes D, Cowell W, Koncz T, Cramer J. Methods for integrating medication compliance and persistence in pharmacoeconomic evaluations. Value Health 2007; 10: 498–509.
12. World Health Organization Collaborating Centre for Drug Statistics Methodology. Anatomical Therapeutic Chemical Code Classification index with Defined Daily Doses. 2004 [cited 2004 Feb 4]; Available from: http://www.whocc.no/atcddd/.
13. Donnelly N, McManus P, Dudley J, Hall W. Impact of increasing the re-supply interval on the seasonality of subsidised prescription use in Australia. Aust N Z J Public Health 2000; 24: 603–606.
14. Poluzzi E, Strahinja P, Vaccheri A, Vargiu A, Silvani MC, Motola D, et al. Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. Br J Clin Pharmacol 2007; 63: 346–355.
15. Hudson M, Rahme E, Richard H, Pilote L. Comparison of measures of medication persistency using a prescription drug database. Am Heart J 2007; 153: 59–65.
16. Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004; 117: 73–81.
17. Gogovor A, Dragomir A, Savoie M, Perreault S. Comparison of persistence rates with angiotensin-converting enzyme inhibitors used in secondary and primary prevention of cardiovascular disease. Value Health 2007; 10: 431–441.
18. Foody JM, Joyce AT, Rudolph AE, Liu LZ, Benner JS. Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study. Curr Med Res Opin 2008; 24: 1987–2000.
19. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW, Stang MR, Semchuk WM. Adherence to statins, beta-blockers and angiotensin-converting enzyme inhibitors following a first cardiovascular event: a retrospective cohort study. Can J Cardiol 2005; 21: 485–488.
20. Grant RW, O'Leary KM, Weilburg JB, Singer DE, Meigs JB. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med 2004; 164: 2343–2348.
21. Gregoire J, Moisan J, Guibert R, Ciampi A, Milot A. Predictors of self-reported noncompliance with antihypertensive drug treatment: a prospective cohort study. Can J Cardiol 2006; 22: 323–329.
22. Australian Institute of Health and Welfare A, Health care usage and costs. A comparison of veterans and war widows and widowers with the rest of the community. in Cat. no. PHE 42. Canberra: AIHW; 2002.
23. Australia. National Health Act. 1953.
24. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA 1998; 279: 1458–1462.
25. Hallas J. Drug utilization statistics for individual-level pharmacy dispensing data. Pharmacoepidemiol Drug Saf 2005; 14: 455–463.